cas 117048-56-3|| where to buy (8S,10S,13S,14S)-17-acetyl-10,13-dimethyl-6,7,8,12,14,15-hexahydrocyclopenta[a]phenanthren-3-one

Product Name:(8S,10S,13S,14S)-17-acetyl-10,13-dimethyl-6,7,8,12,14,15-hexahydrocyclopenta[a]phenanthren-3-one

IUPAC Name:(3aS,3bS,9aS,11aS)-1-acetyl-9a,11a-dimethyl-3H,3aH,3bH,4H,5H,7H,9aH,11H,11aH-cyclopenta[a]phenanthren-7-one

Packing Unit	Available Stock	Price($)	Quantity

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 117048-56-3 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:117048-56-3; Molecular Formula:C21H24O2; Melting Point:-; Smiles Code:CC(=O)C1=CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]12C; Density:

: Catalog Number:CM734660; Molecular Weight:308.42; Boiling Point:; MDL No:MFCD13195553; Storage:

: Cyclohexanes; Cyclohexane is an organic compound with a chemical formula C6H12. It is a colorless liquid with a pungent odor, insoluble in water, and soluble in most organic solvents such as ethanol, ether, benzene, and acetone. Cyclohexyl fragments are a common structure in both natural and synthetic drugs. It can be used as both core structure and part of achiral side chain.

: Vamorolone; Dec 18, 2023, AGAMREE (vamorolone) has been approved in the European Union (EU) for the treatment of DMD in patients 4 years of age and older.
Duchenne muscular dystrophy (DMD) is a genetic muscle disease. And The feature is contraction-induced myofibre injury and inflammation. Researchers found that NF-κB signaling is active in dystrophin deficient muscle. Therefore, Inhibiting NF-κB is a potent strategy for the treatment of DMD. Vamorolone is an investigational drug that was developed as a novel dissociative steroidal anti-inflammatory. This means that its chemical profile is such that it shows chemical separation of efficacy (clinical benefit) from some safety concerns (side effect profiles) typically seen with corticosteroids.
AGAMREE is the only approved medication in the EU for treating DMD, and the first DMD treatment approved in both the U.S. and EU.